Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer

Exclusion Criteria

• •1. Allergy to paclitaxel for injection (albumin binding) and/or its adjuvants has been demonstrated;
• •2. Pregnant or lactating women
• •3. Abnormal results of physical examination and laboratory examination 1) Absolute neutrophil count (ANC) 90g/L 1.5 × 109/L; Platelets (PLT) 90g/L 100 × 109/L; Hemoglobin (Hgb) \< 90g/L 2) Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]/ alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\]) \>2.5 × institutional upper limit of normal (ULN), \>5 × institutional upper limit of normal (ULN) (hepatic metastases); Total bilirubin (TBIL)\>1.5 × ULN; 3) Creatinine (CRE)\> 1.5 × ULN 4) Prothrombin time (PT) and international normalized ratio (INR) \> 1.5 × ULN. Unless the subject had received anticoagulant treatment
• •4. Paclitaxel for injection (albumin binding type) contraindications in patients
• •5. Participating in clinical trials of other taxoids
• •6. Patients with concomitant other tumors, other than cured carcinoma in situ of the cervix and non-melanoma skin cancer
• •7. Participation in any trial drug treatment or another interventional clinical trial 30 days before screening period.
• •8. The researchers considered that there were other conditions that were not suitable for enrollment.